Development Candidate. A Development Candidate shall have been deemed to have been nominated upon the earlier of the date (i) the Schering-Plough Research Institute Project Assessment Committee or its successor approves proceeding with full development of such compound, or (ii) SPL (or its Affiliate) initiates in vivo toxicology trials necessary, and meeting U.S. FDA (or corresponding European or Japanese) standards, for obtaining approval for use of such Agreement Compound in human clinical trials. Within thirty (30) days after the nomination of a Development Candidate, SPL shall notify Pharmacopeia thereof.
Development Candidate. The term “Development Candidate” shall mean a Collaboration Product that meets all of the Development Candidate criteria that is set forth in the applicable Joint Research Plan, or alternative criteria agreed to on a Collaboration Target-by-Collaboration Target basis by the JRC (“Development Candidate Criteria”).
Development Candidate. The mouse antibody [***] is a lead molecule. The antibody V-regions will be converted into human V-regions. The importance of valency, ephrin A5 and drug conjugates will be factored into the design of the development candidate. Optimization of effector functions will be considered.
Development Candidate. A Development Candidate shall have been ---------------------------- deemed to have been nominated upon the earlier of the date (i) the Schering- Plough Research Institute Project Assessment Committee or its successor approves proceeding with full development of such compound, or (ii) Schering (or its Affiliate) initiates in vivo toxicology trials necessary, and meeting U.S. FDA ------- (or corresponding European or Japanese) standards, for obtaining approval for use of such Agreement Compound in human clinical trials. Within thirty (30) days after the nomination of a Development Candidate, Schering shall notify Pharmacopeia thereof, which notification will include identification of the applicable Target(s) (in coded form only) and the general therapeutic area relevant to such Target.
Development Candidate. 3 1.11 Field....................................................3 1.12 First Commercial Sale....................................3 1.13 FTE......................................................3 1.14
Development Candidate. UNITY designates the Ascentage compound known as APG-1197 (also known as BM-1197 and UBX-1967) having the chemical structure set forth below to be a Development Candidate (as defined in the Library Agreement). APG-1197 [***]
Development Candidate. Upon the earlier to occur of: (i) the Collaboration Committee’s confirmation that any [*] meets the [*] for its [*]; or (ii) EXEL’s submission to GSK of the [*] described in [*] with respect to [*] that meet the Activity Threshold with respect to [*] and for which EXEL has completed [*], GSK shall pay EXEL a one-time [*] milestone payment of Five Million Dollars ($5,000,000) within [*] after such submission. Such milestone payment is not [*] nor shall EXEL be obligated to [*]; provided, however, that, subject to [*], EXEL shall [*] in furtherance of [*] over the [*].
Development Candidate. Lilly shall have the option to license each Development Candidate in accordance with Section 8.2.3.
Development Candidate. Isis will notify Biogen Idec in writing within 30 days of designating a Development Candidate and will provide Biogen Idec the applicable Development Candidate Data Package.
Development Candidate. During the period that Organon has a license under Section 5.4 to a Lead Compound, Organon may designate any Lead Compound or Derivative Compound as a Development Candidate. Organon shall provide written notice to Pharmacopeia to such effect and such designation shall trigger the milestone payment for initiation of GLP Toxicity Studies set forth in Section 7.1.
